Tianjin Zhongxin Pharmaceutical Group Corp Ltd Total Liabilities
Tianjin Zhongxin Pharmaceutical Group Corp Ltd total liabilities. Based on the latest financial reports, Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329) has total liabilities worth CN¥2.56 Billion CNY (≈ $374.76 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Tianjin Zhongxin Pharmaceutical Group Co (600329) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Tianjin Zhongxin Pharmaceutical Group Corp Ltd (1998–2024)
Total liabilities of Tianjin Zhongxin Pharmaceutical Group Corp Ltd from 1998 to 2024. This chart illustrates how Tianjin Zhongxin Pharmaceutical Group Corp Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Tianjin Zhongxin Pharmaceutical Group Co long-term investment intensity to see how much of total assets are deployed in long-term investments.
Tianjin Zhongxin Pharmaceutical Group Corp Ltd Competitors by Total Liabilities
The table below lists competitors of Tianjin Zhongxin Pharmaceutical Group Corp Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Strauss Group
TA:STRS
|
Israel | ILA5.19 Billion |
|
Jiangsu Phoenix Publishing & Media Corp Ltd
SHG:601928
|
China | CN¥11.19 Billion |
|
Shenzhen Yan Tian Port Holdings Co Ltd
SHE:000088
|
China | CN¥4.15 Billion |
|
Changsha Jingjia Microelectronics Co Ltd
SHE:300474
|
China | CN¥937.88 Million |
|
Amcor plc
F:485
|
Germany | €25.40 Billion |
|
QL Resources Bhd
KLSE:7084
|
Malaysia | RM2.47 Billion |
|
JC Decaux SA
PA:DEC
|
France | €5.82 Billion |
Liability Composition Analysis (1998–2024)
This chart breaks down Tianjin Zhongxin Pharmaceutical Group Corp Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Tianjin Zhongxin Pharmaceutical Group Co.
Liquidity & Leverage Metrics
Tianjin Zhongxin Pharmaceutical Group Corp Ltd Total Liabilities Ratios Explained
Tianjin Zhongxin Pharmaceutical Group Corp Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tianjin Zhongxin Pharmaceutical Group Corp Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tianjin Zhongxin Pharmaceutical Group Corp Ltd (1998–2024)
The table below shows the annual total liabilities of Tianjin Zhongxin Pharmaceutical Group Corp Ltd from 1998 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.92 Billion ≈ $427.10 Million |
-18.58% |
| 2023-12-31 | CN¥3.58 Billion ≈ $524.58 Million |
-0.56% |
| 2022-12-31 | CN¥3.61 Billion ≈ $527.53 Million |
+41.19% |
| 2021-12-31 | CN¥2.55 Billion ≈ $373.62 Million |
+9.42% |
| 2020-12-31 | CN¥2.33 Billion ≈ $341.46 Million |
+0.58% |
| 2019-12-31 | CN¥2.32 Billion ≈ $339.48 Million |
+13.12% |
| 2018-12-31 | CN¥2.05 Billion ≈ $300.11 Million |
+2.73% |
| 2017-12-31 | CN¥2.00 Billion ≈ $292.12 Million |
-3.02% |
| 2016-12-31 | CN¥2.06 Billion ≈ $301.21 Million |
+4.82% |
| 2015-12-31 | CN¥1.96 Billion ≈ $287.35 Million |
-21.15% |
| 2014-12-31 | CN¥2.49 Billion ≈ $364.45 Million |
-7.32% |
| 2013-12-31 | CN¥2.69 Billion ≈ $393.25 Million |
+25.48% |
| 2012-12-31 | CN¥2.14 Billion ≈ $313.40 Million |
+10.48% |
| 2011-12-31 | CN¥1.94 Billion ≈ $283.67 Million |
+10.80% |
| 2010-12-31 | CN¥1.75 Billion ≈ $256.02 Million |
-6.88% |
| 2009-12-31 | CN¥1.88 Billion ≈ $274.94 Million |
-4.73% |
| 2008-12-31 | CN¥1.97 Billion ≈ $288.60 Million |
-7.27% |
| 2007-12-31 | CN¥2.13 Billion ≈ $311.21 Million |
+1.36% |
| 2006-12-31 | CN¥2.10 Billion ≈ $307.05 Million |
-0.41% |
| 2005-12-31 | CN¥2.11 Billion ≈ $308.31 Million |
+3.50% |
| 2004-12-31 | CN¥2.04 Billion ≈ $297.89 Million |
+3.95% |
| 2003-12-31 | CN¥1.96 Billion ≈ $286.56 Million |
+48.48% |
| 2002-12-31 | CN¥1.32 Billion ≈ $192.99 Million |
+11.91% |
| 2001-12-31 | CN¥1.18 Billion ≈ $172.46 Million |
-14.37% |
| 2000-12-31 | CN¥1.38 Billion ≈ $201.39 Million |
+348.34% |
| 1999-12-31 | CN¥306.96 Million ≈ $44.92 Million |
+39.19% |
| 1998-12-31 | CN¥220.53 Million ≈ $32.27 Million |
-- |
About Tianjin Zhongxin Pharmaceutical Group Corp Ltd
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmologic… Read more